个股异动 | 金迪克两连板 相关儿童流感疫苗开展Ⅲ期临床试验

Core Viewpoint - Jindike experienced a significant stock price increase, closing at 24.97 yuan per share, up 19.99%, marking its second consecutive trading limit up, with related flu concept stocks also rising [1] Company Overview - Jindike's main business includes research and production in biotechnology, particularly in the development of vaccines and related biological products [1] - The company is actively advancing its research projects to meet market demands, as evidenced by its ongoing Phase III clinical trials for the quadrivalent influenza virus split vaccine for children [1] Financial Performance - In the third quarter, Jindike reported a total R&D expenditure of 17.93 million yuan, which accounted for 25.21% of its operating revenue [1] - The increase in R&D expenses is primarily attributed to the Phase III clinical trials for the quadrivalent influenza virus split vaccine for children, indicating a year-on-year rise in R&D investment [1]